Remuzzi Giuseppe, Schiaffino Stefano, Santoro Maria Gabriella, FitzGerald Garret A, Melino Gennaro, Patrono Carlo
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Venetian Institute of Molecular Medicine (VIMM), Padova, Italy.
Front Pharmacol. 2022 Oct 10;13:987816. doi: 10.3389/fphar.2022.987816. eCollection 2022.
The COVID-19 Committee of the Lincei Academy has reviewed the scientific evidence supporting the efficacy and safety of existing and new drugs/biologics for the preventing and treating of COVID-19 and its complications. This position paper reports what we have learned in the field in the past 2 years. The focus was on, but not limited to, drugs and neutralizing monoclonal antibodies, anti-SARS-CoV-2 agents, anti-inflammatory and immunomodulatory drugs, complement inhibitors and anticoagulant agents. We also discuss the risks/benefit of using cell therapies on COVID-19 patients. The report summarizes the available evidence, which supports recommendations from health authorities and panels of experts regarding some drugs and biologics, and highlights drugs that are not recommended, or drugs for which there is insufficient evidence to recommend for or against their use. We also address the issue of the safety of drugs used to treat underlying concomitant conditions in COVID-19 patients. The investigators did an enormous amount of work very quickly to understand better the nature and pathophysiology of COVID-19. This expedited the development and repurposing of safe and effective therapeutic interventions, saving an impressive number of lives in the community as well as in hospitals.
林琴科学院新冠委员会审查了支持现有及新药/生物制品预防和治疗新冠病毒疾病（COVID-19）及其并发症的有效性和安全性的科学证据。本立场文件报告了我们在过去两年中在该领域的所学。重点关注但不限于药物和中和单克隆抗体、抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）药物、抗炎和免疫调节药物、补体抑制剂及抗凝剂。我们还讨论了对COVID-19患者使用细胞疗法的风险/益处。本报告总结了现有证据，这些证据支持卫生当局和专家小组对某些药物和生物制品的建议，并突出了不推荐使用的药物，或没有足够证据推荐使用或反对使用的药物。我们还讨论了用于治疗COVID-19患者基础合并症的药物的安全性问题。研究人员迅速开展了大量工作，以更好地了解COVID-19的性质和病理生理学。这加快了安全有效治疗干预措施的开发和重新利用，在社区和医院挽救了大量生命。
